Last reviewed · How we verify
Yervoy
Yervoy, developed by Bristol-Myers Squibb, is a marketed drug primarily indicated for high grade squamous intraepithelial neoplasia of the esophagus. A key strength of Yervoy is its mechanism of action, which differentiates it in the treatment landscape. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Yervoy |
|---|---|
| Also known as | Ipilimumab, ipilimumab |
| Sponsor | Bristol-Myers Squibb |
| Target | Cytotoxic T-lymphocyte protein 4 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- High grade squamous intraepithelial neoplasia of esophagus
- Metastatic malignant melanoma
- Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation
- Microsatellite instability-high colorectal cancer
- Renal cell carcinoma
- Unresectable advanced or recurrent esophageal cancer
- Unresectable advanced or recurrent malignant pleural mesothelioma
Common side effects
- Fatigue
- Diarrhea
- Pruritus
- Rash
- Nausea
- Headache
- Musculoskeletal pain
- Pyrexia
- Cough
- Decreased appetite
- Vomiting
- Abdominal pain
Serious adverse events
- Colitis
- Diarrhea
- Fatigue
- Rash
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |